Lonza Expands Solid Form Services for Small Molecule Drugs

Basel, Switzerland, 16 February 2021 – Lonza announced today an expansion of its solid form selection services based at its Bend, OR (USA) site. The increased service capabilities and dedicated team complement previously established SimpliFiH® Solutions first-in-human services consisting of phase-appropriate drug substance and drug product development and manufacture. The solid form services offering also enhances Lonza’s capabilities in meeting accelerated timelines for increasingly complex molecules.

The selection of a lead solid involves the screening and characterization of both chemical forms (salts, cocrystals, solvates) and the associated polymorphs. Every molecule has a different propensity for polymorphism and to form hydrates and solvates. The molecule's physicochemical properties and the target product profile dictate the need for screening salts, cocrystals, or bioavailability-enhanced formulations, and the key properties of any solid form: solubility, dissolution rate, manufacturability, stability, etc. Effective screening and selection are critical for early-stage and late-stage development to further process risk reduction and/or strengthen intellectual property claims.

Lonza’s solid form services are comprehensive, including form and salt/cocrystal screening, solid state characterization, chemical composition, solubility and dissolution, and powder properties.

For more information on solid form services, visit

About Lonza 

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector. 

Founded in 1897 in the Swiss Alps, today Lonza operates across three continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at 

Follow @Lonza on LinkedIn 
Follow @LonzaGroup on Twitter

Lonza Contact Details 

Dr. Sanna Fowler 
Head of External Communications 
Lonza Group Ltd 
Tel 41 61 316 8929 

Dirk Oehlers 
Investor Relations 
Lonza Group Ltd 
Tel 41 61 851 4927 

Additional Information and Disclaimer 

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. 

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.